India  

"Dr Reddy"

Latest news and video coverage curated from trusted media outlets

0
shares
ShareTweetSavePostSend
 

You Might Like


Zambon Taps Kinaxis to Enhance Transparency Across Global Supply Chain

*Business Wire India*Kinaxis^® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced Zambon, a multinational pharmaceutical company committed to innovating cure..
Business Wire India - Published

INVNT Scales South Asia Presence with Breakthrough Brand Activations, Immersive Storytelling, and Cultural-First Experiences

*Business Wire India*INVNT®, the global live brand storytelling agency, is accelerating its presence across South Asia and redefining what it means to build culture through creativity. Since opening..
Business Wire India - Published

Dr Reddy's receives two USFDA observations for New York API facility

Dr. Reddy's Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these..
IndiaTimes - Published

SBI, NTPC Green Energy, Yes Bank, IndusInd Bank, Adani Power, Swiggy, Dr. Reddy's Share Price in Focus


TopNews - Published

Dr Reddy’s Q4 net profit rises 21% to Rs 1,587 crore on strong global sales

Dr. Reddy's Laboratories announced a 21% surge in net profit, reaching Rs 1,587 crore for the March 2025 quarter, fueled by strong sales in the US and India. Annual profit saw a modest 3% rise to Rs..
IndiaTimes - Published

'Factually incorrect': Dr Reddy's denies report on 25 pc workforce cost cuts, laying off highly-paid staff


newKerala.com - Published

Pharma co Dr Reddy's to reduce costs


IndiaTimes - Published

Dr Reddy's cuts workforce cost by 25 pc, lays off employees above Rs 1 cr package: Report


newKerala.com - Published Also reported by •Zee News

'Factually incorrect': Dr. Reddy clears air amid workforce reduction rumors

Dr. Reddy's Laboratories has refuted media reports alleging a 25% reduction in workforce costs. The Hyderabad-based pharmaceutical giant dismissed claims of layoffs targeting high-earning employees and..
IndiaTimes - Published

Dr Reddy's layoffs: Pharma firm cuts workforce cost by 25 per cent, asks even senior employees earning Rs 1 crore to quit

Employees in the age group of 50-55 years working in Dr Reddy's research and development (R&D) division have been offered a voluntary retirement, a report said. The pharma company currently has a..
DNA - Published

Dr Reddy's inks South East Asia commercialisation, licence pacts with China's Bio-Thera for Stelara, Simponi biosimilars


IndiaTimes - Published

Dr Reddy's Q3 PAT rises 2% despite 16% jump in revenues


IndiaTimes - Published

Dr Reddy's Q3 profit up 2% at Rs 1,413 crore; revenue at Rs 8,359 crore

Dr Reddy's Laboratories saw a 2% rise in consolidated net profit to Rs 1,413 crore in Q3 FY24, driven by strong market performance. Revenue grew to Rs 8,359 crore, with notable growth in the US,..
IndiaTimes - Published

Sensex, Nifty end on a positive note on first trading session of 2025

sensex, nifty end on a positive note on first trading session of 2025
Among the top gainers were Maruti, M&M, LT, Bajaj Finance, and Tata Motors, which saw strong upward movements, while Hindalco, Dr Reddy`s, Adani Ports, ONGC, and Tata Steel struggled, contributing to..
Mid-Day - Published

Meet man with Rs 26858 crore net worth, runs Rs 104268 crore company, his business is...

Dr. Reddy's daughters: Preetha, Suneeta, Shobana, and Sangita now take the reins of the business, and his careful mentorship is part of the process.
DNA - Published

Dr Reddy launches world's 1st immuno-onco drug for nasopharyngeal cancer in India

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head..
IndiaTimes - Published

Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel

Dr Reddy’s Laboratories' subsidiary, Aurigene Oncology Limited, received DCGI approval to conduct a phase-2 trial for India's first novel autologous BCMA directed CAR-T cell therapy, Ribrecabtagene..
IndiaTimes - Published

Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120..
IndiaTimes - Published

'Madhabi Buch investing in Chinese firms': Congress ups ante against Sebi chief

Congress has accused Sebi chief Madhabi Puri-Buch of making high-value investments in Chinese firms during geopolitical tensions and trading in listed securities with unpublished price-sensitive..
IndiaTimes - Published

Hindenburg Research alleges SEBI chief Madhabi Puri Buch's firm illegally accepted payments from listed entities

Hindenburg named Mahindra & Mahindra, ICICI Bank, Dr Reddy's Laboratories, and Pidilite Industries as among the companies that allegedly paid the consulting firm.
DNA - Published

IIM Mumbai Unveils Plans for Rs. 800 Crore State-of-the-Art Facilities for Students and Innovation

iim mumbai unveils plans for rs. 800 crore state-of-the-art facilities for students and innovation
On its Foundation Day, IIM Mumbai has announced an investment of INR 800 crores for its campus enhancement project. This significant investment will help towards modernizing and developing..
NewsVoir - Published

TEDx Marwadi University Inspires Students with a 'Kaleidoscope of Ideas'

tedx marwadi university inspires students with a 'kaleidoscope of ideas'
With a view to creating a platform for the exchange of ideas and perspectives, Marwadi University in Rajkot recently hosted the TEDx Marwadi University event. The event, themed 'Kaleidoscope of Ideas',..
NewsVoir - Published

Dr Reddy’s Labs most valued family business from Telangana

The 2024 Barclays Private Clients and Hurun India rankings revealed that the Prasad and Reddy family of Dr Reddy's Laboratories topped as the most valuable family business from Telangana, valued at Rs..
IndiaTimes - Published

Dr Reddy's invests Rs 734 crore in JV with Nestle India

Dr Reddy's Laboratories invested over Rs 734 crore for a 51% stake in a joint venture with Nestle India, which invested Rs 705.6 crore for the remaining 49%. The JV focuses on health and nutrition..
IndiaTimes - Published

Dr Reddy’s Rituximab biosimilar Ituxredi gets EMA CHMP positive recommendation

Dr Reddy’s Laboratories announced that the EMA’s committee recommended its Rituximab biosimilar Ituxredi for the European market. The decision will be reviewed by the European Commission for final..
IndiaTimes - Published

Higher tax outgo dents Dr Reddy’s Q1 net profit


IndiaTimes - Published

Dr Reddy’s to buy UK company's nicotine gum business for Rs 5,000 crore

Dr Reddy's Laboratories is set to acquire Haleon Plc's NRT business, including Nicotinell, for GBP 500 million. The deal encompasses various NRT formats and potential contingent payments. This..
IndiaTimes - Published

Dr Reddy's Q4 net profit up 36%


IndiaTimes - Published

Dr Reddy’s initiates voluntary recall of Sapropterin Dihydrochloride in US over potency concerns


IndiaTimes - Published

Dr Reddy’s rolls out migraine management device Nerivio in Europe


IndiaTimes - Published

Dr Reddy's to exclusively distribute Sanofi's vaccine portfolio in India

Dr Reddy’s Laboratories on Wednesday informed the bourses has entered into an exclusive partnership with Sanofi Healthcare India Pvt Ltd for the distribution of the latter’s vaccine portfolio in..
IndiaTimes - Published

Dr Reddy's ties up with US firm for resuscitative therapy


IndiaTimes - Published

Megha, Yashoda hospital, pharma companies kept BRS in good health

MEIL was the biggest donor to BRS with Rs 195 crore. Yashoda Hospital followed with Rs 94 crore. Dr Reddy’s Lab and Hetero Drugs contributed Rs 32 crore and Rs 30 crore, respectively.
IndiaTimes - Published

BJP, BRS & Cong top recipients of donations from pharma firms

BJP, BRS, Congress dominated pharma donations through electoral bonds, with BJP receiving the highest amount. Aurobindo Pharma, whose director was arrested in an excise scam, is also one of the donors..
IndiaTimes - Published

Booster shot: Sector biggies to make Uttar Pradesh a pharma hub

Dr Reddy’s Laboratory, Rockwell Automation, and other Telangana pharmaceutical companies plan to invest in Uttar Pradesh. They are attracted by the pro-pharma policies of the Yogi government. The..
IndiaTimes - Published

Pharma, Healthcare Stocks Top Sectoral Gainers In Trade

Sun Pharma is the top Sensex gainer with gains of more than 3 per cent. Dr Reddy's is up more than 4 per cent. Max Healthcare is up 6 per cent.
Zee News - Published

Dr Reddy’s acquires MenoLabs women’s wellness portfolio from Amyris

Dr Reddy's Laboratories acquires Amyris Inc's MenoLabs portfolio, a women's health and dietary supplement brand, as part of Amyris' Chapter 11 bankruptcy sales proceedings. The acquisition includes..
IndiaTimes - Published

United States: BPCIA Complaint Against Proposed Rituxan® Biosimilar DRL_RI Filed - Venable LLP

On November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. ("Plaintiffs") filed a BPCIA complaint ("Complaint") against Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories SA..
Mondaq - Published

Dr Reddy's becomes sole Indian pharma player to make it to Dow Jones Sustainability World Index 2023

Dr Reddy's Laboratories becomes the first and only Indian pharma company on the S&P Dow Jones Sustainability World Index for 2023. The company also retains its position on the Dow Jones Sustainability..
IndiaTimes - Published

Pharma faces USFDA heat, stocks down

The stocks of several pharma companies, including Dr Reddy's, Aurobindo Pharma, Cipla, Lupin, Sun Pharma, and Divi's Labs, have been lagging behind as the sensex and Nifty reach new highs. Dr Reddy's..
IndiaTimes - Published

Dr Reddy's inks pact with Coya Therapeutics for investigational ALS therapy COYA 302

Dr Reddy's Laboratories SA, a subsidiary of Dr Reddy's Laboratories, has signed a development and licence agreement with Coya Therapeutics Inc for the development and commercialisation of COYA 302, a..
IndiaTimes - Published

Experts Urge for Preventive Lifestyle and Awareness on Treatment Options at the Osteoporosis Awareness Summit

The experts at the Osteoporosis Awareness Summit observed that osteoporosis is a public health emergency, however early screening and preventive lifestyle can help in proactive management and effective..
NewsVoir - Published

Dr Reddy's Bachupally biologics facility gets USFDA Form 483 with 9 observations

On Thursday, Dr. Reddy's Laboratories, a prominent pharmaceutical company, disclosed to the stock exchanges that it has been issued a Form 483 containing nine observations by the US Food & Drug..
IndiaTimes - Published

India: Delhi High Court Rules In Favour Of Reddy's Laboratories On Use Of The Mark RAZOFAST By Fast Cure Pharma - LexOrbis

In the recent case of Dr. Reddy's Laboratories Ltd vs Fast Cure Pharma, the plaintiff applied to the Delhi High Court for a permanent injunction restraining the defendant from manufacturing...
Mondaq - Published


 Page 1  〉